Intralink-Spine expands clinical trials to Australia, New Zealand: 4 takeaways

Intralink-Spine expanded its clinical studies to Australia and New Zealand through Five Corners, a Sydney, Australia-based contract research organization.

Advertisement

Here are four takeaways.

1. Five Corners will assist Intralink-Spine in their journey to obtain the CE Mark for its Réjuve medical device.

2. The Réjuve is an injectable medical device intended to treat degenerative disc disease, low back pain, scoliosis and more.

3. Intralink-Spine reported positive 12-month results, reflecting Réjuve’s ability to reduce or eliminate low back pain and disability.

4. Tom Hedman, PhD, invented the device. He serves as an adjunct associate professor in biomedical engineering at the University of Kentucky in Lexington.

More articles on devices:
Zimmer Biomet signs agreement with Department of Energy to reduce energy use by 25%: 5 takeaways
Zimmer Biomet vs. Amedica — Which company reported $7.82B in gross revenues?
5 things to know about Medtronic CFO Karen Parkhill

 

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

  • From new product launches and leadership appointments, here are seven key headlines from Stryker in the first quarter of 2026.…

  • Xtant Medical’s 2025 revenue reached $133.9 million, a 14% increase year over year, according to financial results posted March 31.…

Advertisement

Comments are closed.